Stock Movers Grail Plunges; Deere, Herbalife Rise
Feb 19, 2026
A tech lab’s multi-cancer screening test misses a key trial goal, triggering a sharp stock drop. Farm-equipment titan lifts its profit outlook and posts a six-year high on optimism for agriculture. A wellness company’s shares jump after a famous athlete backs a new health-tracking service.
AI Snips
Chapters
Transcript
Episode notes
Galleri Misses Key Clinical Goal
- Grail's Galleri test failed to show a statistically significant drop in combined Stage III and IV cancers in its key endpoint.
- That outcome undermines the test's core value proposition of earlier detection improving outcomes and may hinder broader adoption.
Regulatory And Commercial Impact Looms
- Missing the primary endpoint could make it harder to sell Galleri to national health systems like the NHS.
- The result also triggered a sharp after-hours price reaction, reflecting investor concern about commercial prospects.
Deere Prices In Farm Rebound
- Deere raised its annual profit outlook, signaling an expected upturn in the agriculture economy.
- The stock jumped to a multi-decade high as investors priced in a crop-cycle recovery not shared by some peers.